Success Stories: EB-1A Approved for Visiting Research Associate in Colorado in the Field of Pharmacology

Client’s Testimonial:

 

This is a very good news. You did outstanding job in preparation of my application.
 


On September 26th, 2014, We Received Another EB1-A (Alien of Extraordinary Ability) Approval for a Visiting Research Associate in the Field of Pharmacology (Approval Notice)


General Field: Pharmacology

Position at the Time of Case Filing: Visiting Research Associate

Country of Origin: India

Service Center: Nebraska Service Center (NSC)

State of Residence at the Time of Filing: Colorado

Approval Notice Date: September 26th, 2014

Processing Time: 3 Months, 28 Days


Case Summary:

In this case, the client that we had the opportunity to work with was a Visiting Research Associate from India in the field of Pharmacology.  His specialized research has focused on developing an array of naturally occurring compounds for use in the treatment of everything from cancer to mustard gas attacks. His work had resulted in 24 peer-reviewed scientific articles and numerous presentations at national and international conferences; at the time that his case was filed, his publications had been cited at least 161 times by independent and leading researchers from prestigious institutions and organizations around the world, indicating the major significance of his work.  He had also reviewed 12 manuscripts for distinctive, internationally-circulated journals.  His superior level of expertise was confirmed in the following quote from an independent recommender, “[Client] studied stromal cell proliferation and differentiation ( decasualization) and found that the specific prostaglandins PGE2 and PGI2 are important in these stages of development. Therefore, his study elucidated an important mechanism for fertility treatments and techniques.” It was our goal to prove that our client qualified for classification as an Alien of Extraordinary Ability given that he sought to remain in the United States to continue work in the area of Pharmacology, and that his continued research would substantially and prospectively benefit the United States. With the proof and documentation that we provided, his case was approved in 3 months and 28 days.